Par Drugs and Chemicals News
- Market cap
- ₹145 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹84.78 – ₹158.96
The latest update on Par Drugs and Chemicals is "Par Drugs and Chemicals Limited Reports Operational Performance & Quarterly Growth Update" (BSE Corporate Announcement), published 9 October 2026. This page lists 4 recent headlines and exchange announcements, 2 of them filed on BSE. Par Drugs and Chemicals' next board meeting for results is scheduled for 3 November 2026.
Latest Par Drugs and Chemicals news and announcements
Next results board meeting: 3 November 2026.
- Par Drugs and Chemicals Limited Reports Operational Performance & Quarterly Growth Update
- Market Activity: Par Drugs and Chemicals Limited Shares See Strong Institutional Volume
- Par Drugs and Chemicals Limited Board Compliances & Mandatory Disclosure Filings Submitted
- Analyst Review: Key Valuation Overview & Target Projection for Par Drugs and Chemicals Limited
Source: Publisher headlines and announcements filed on BSE, linked to their original sources. Data as of 9 October 2026. How this data is compiled.
Par Drugs and Chemicals news & announcements — frequently asked questions
What is the latest news on Par Drugs and Chemicals?
The most recent item is "Par Drugs and Chemicals Limited Reports Operational Performance & Quarterly Growth Update" from BSE Corporate Announcement on 9 October 2026. The full list above links to each original source.
When are Par Drugs and Chemicals' next results?
Par Drugs and Chemicals has announced a board meeting on 3 November 2026 to consider its financial results, according to its filing on BSE.
Where do these Par Drugs and Chemicals headlines come from?
Headlines link to the original publisher, and exchange announcements link to the filing on BSE. ATS lists them by date and does not rewrite or summarise them.
Same Data For Peers
Trade Par Drugs and Chemicals With ATS
Track PAR live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.